TrialMovement disorders : official journal of the Movement Disorder Society2015

NBI-98854, a selective monoamine transport inhibitor for the treatment of tardive dyskinesia: A randomized, double-blind, placebo-controlled study.

Christopher F O'Brien et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.